(Total Views: 485)
Posted On: 03/24/2021 9:20:13 PM
Post# of 36568
I’m not Generex, but to the best of my knowledge:
The IPO isn’t dependent upon further vaccine development. It’s set to go pending bank pricing.
The bonuses are mainly retroactive salary reimbursement for the last few years. It’s been noted in the last 2 Qs, so obviously the CEO is awaiting optimal timing. It has nothing to do with the NGIO IPO.
Once NGIO is listed on Nasdaq there are annual shareholder meetings.
Jmho. Call Joe or Todd.
The IPO isn’t dependent upon further vaccine development. It’s set to go pending bank pricing.
The bonuses are mainly retroactive salary reimbursement for the last few years. It’s been noted in the last 2 Qs, so obviously the CEO is awaiting optimal timing. It has nothing to do with the NGIO IPO.
Once NGIO is listed on Nasdaq there are annual shareholder meetings.
Jmho. Call Joe or Todd.
(4)
(0)
